Analyst Ratings for 89bio
Over the past 3 months, 7 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Raymond James Maintains Strong Buy on 89bio, Raises Price Target to $25
Raymond James analyst Steven Seedhouse maintains 89bio (NASDAQ:ETNB) with a Strong Buy and raises the price target from $14 to $25.
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
US Stocks Open Lower After Inflation Report, Dow Dips 700 Points
U.S. stocks traded sharply lower this morning, following the release of inflation data for August
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…
89bio’s Pegozafermin Data Shows Improved Liver Fat, Glycemic Control
89bio Inc (NASDAQ:ETNB) announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG)…
